Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of $0.01, $0.12 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $154.7 million versus the consensus estimate of $146.73 million.

2025 Financial Guidance

Amicus reiterates its financial guidance for 2025, as follows:

Total Revenue Growth 15% to 22%
Galafold Revenue Growth 10% to 15%
Pombiliti + Opfolda Revenue Growth1 50% to 65%
Gross Margin Mid 80%
Non-GAAP Operating Expenses4 $380M to $400M (Incl. $30M Upfront License Payment)
GAAP Net Income Positive during H2 2025

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.